Transparency in Nigeria's public pharmaceutical sector: perceptions from policy makers

被引:36
|
作者
Garuba, Habibat A. [1 ]
Kohler, Jillian C. [1 ]
Huisman, Anna M. [1 ]
机构
[1] Univ Toronto, Leslie Dan Fac Pharm, Toronto, ON, Canada
来源
关键词
Good Manufacture Practice; Corrupt Practice; Pharmaceutical Sector; Regulatory Capture; Counterfeit Drug;
D O I
10.1186/1744-8603-5-14
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: Pharmaceuticals are an integral component of health care systems worldwide, thus, regulatory weaknesses in governance of the pharmaceutical system negatively impact health outcomes especially in developing countries [1]. Nigeria is one of a number of countries whose pharmaceutical system has been impacted by corruption and has struggled to curtail the production and trafficking of substandard drugs. In 2001, the National Agency for Food and Drug Administration and Control (NAFDAC) underwent an organizational restructuring resulting in reforms to reduce counterfeit drugs and better regulate pharmaceuticals [2]. Despite these changes, there is still room for improvement. This study assessed the perceived level of transparency and potential vulnerability to corruption that exists in four essential areas of Nigeria's pharmaceutical sector: registration, procurement, inspection (divided into inspection of ports and of establishments), and distribution. Methods: Standardized questionnaires were adapted from the World Health Organization assessment tool and used in semi-structured interviews with key stakeholders in the public and private pharmaceutical system. The responses to the questions were tallied and converted to scores on a numerical scale where lower scores suggested greater vulnerability to corruption and higher scores suggested lower vulnerability. Results: The overall score for Nigeria's pharmaceutical system was 7.4 out of 10, indicating a system that is marginally vulnerable to corruption. The weakest links were the areas of drug registration and inspection of ports. Analysis of the qualitative results revealed that the perceived level of corruption did not always match the qualitative evidence. Conclusion: Despite the many reported reforms instituted by NAFDAC, the study findings suggest that facets of the pharmaceutical system in Nigeria remain fairly vulnerable to corruption. The most glaring deficiency seems to be the absence of conflict of interest guidelines which, if present and consistently administered, limit the promulgation of corrupt practices. Other major contributing factors are the inconsistency in documentation of procedures, lack of public availability of such documentation, and inadequacies in monitoring and evaluation. What is most critical from this study is the identification of areas that still remain permeable to corruption and, perhaps, where more appropriate checks and balances are needed from the Nigerian government and the international community.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] Transparency in Nigeria's public pharmaceutical sector: perceptions from policy makers
    Habibat A Garuba
    Jillian C Kohler
    Anna M Huisman
    Globalization and Health, 5
  • [2] Transparency in public pharmaceutical sector: the key informants' perceptions from a developing country
    Esfandiari, Atefeh
    Yazdi-Feyzabadi, Vahid
    Zarei, Leila
    Rashidian, Arash
    Salari, Hedayat
    BMC HEALTH SERVICES RESEARCH, 2021, 21 (01)
  • [3] Transparency in public pharmaceutical sector: the key informants’ perceptions from a developing country
    Atefeh Esfandiari
    Vahid Yazdi-Feyzabadi
    Leila Zarei
    Arash Rashidian
    Hedayat Salari
    BMC Health Services Research, 21
  • [4] Promotion of Health Sector Reforms for Health Systems Strengthening in Nigeria: Perceptions of Policy Makers versus the General Public on the Nigeria Health Systems Performance
    Uneke, Chigozie Jesse
    Ezeoha, Abel E.
    Ndukwe, C. D.
    Oyibo, P. G.
    Onwe, F.
    SOCIAL WORK IN PUBLIC HEALTH, 2013, 28 (06) : 541 - 553
  • [5] National transparency assessment of Kuwait's pharmaceutical sector
    Badawi, Dalia A.
    Alkhamis, Yousif
    Qaddoumi, Mohammad
    Behbehani, Kazem
    HEALTH POLICY, 2015, 119 (09) : 1275 - 1283
  • [6] Public transport users' and policy makers' perceptions of integrated public transport systems
    Chowdhury, Subeh
    Hadas, Yuval
    Gonzalez, Vicente A.
    Schot, Bart
    TRANSPORT POLICY, 2018, 61 : 75 - 83
  • [7] Moving from opacity to transparency in pharmaceutical policy
    Dhalla, Irfan
    Laupacis, Andreas
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2008, 178 (04) : 428 - 431
  • [8] Use of Scientific Information Sources by Policy Makers in the Science and Technology Sector of Nigeria
    Nwagwu, Williams E.
    Iheanetu, Olamma
    AFRICAN JOURNAL OF LIBRARY ARCHIVES AND INFORMATION SCIENCE, 2011, 21 (01): : 59 - 71
  • [9] Individual and organisational capacity for evidence use in policy making in Nigeria: an exploratory study of the perceptions of Nigeria health policy makers
    Uneke, C. J.
    Ezeoha, A. E.
    Ndukwe, C. D.
    Oyibo, P. G.
    Onwe, F.
    Igbinedion, E. B.
    Chukwu, P. N.
    EVIDENCE & POLICY, 2011, 7 (03): : 251 - 276
  • [10] NUCLEAR-ENERGY - THE ACCURACY OF POLICY MAKERS PERCEPTIONS OF PUBLIC BELIEFS
    THOMAS, K
    SWATON, E
    FISHBEIN, M
    OTWAY, HJ
    BEHAVIORAL SCIENCE, 1980, 25 (05): : 332 - 344